Kordi Tamandani Dor Mohammad, Sobti Ranbir Chander, Shekari Mohammad, Husseini Seyd Ali, Suri Vanita
Department of Biology, Sistan and Baluchistan University, Zahedan, Iran.
J Assist Reprod Genet. 2009 Apr;26(4):173-8. doi: 10.1007/s10815-009-9301-2. Epub 2009 Mar 5.
Transporter associated with antigen processing (TAP), a member of the ATP-binding cassette transporter super family, is composed of two integral membrane proteins, TAP-1 and TAP-2. The TAP gene product is involved in the processing of endogenous peptides that bind to MHC class I molecules. Mutations and/or polymorphism within these genes could alter the efficacy of the immune response which might be relevant for the development of autoimmune diseases and cancer.
DNA was isolated from peripheral blood sample of 200 patients with cervical cancer and 200 healthy controls. TAP1 and TAP2 allele polymorphism were determined by polymerase chain reaction.
Significant protective OR (OR = 0.22 95% CI = 0.09-0.51, P < 0.001-OR = 0.47, 95% CI = 0.24-0.92, P = 0.02) was observed for GG and combined AG+GG genotypes of TAP2 in patients with SCC respectively. Similarly, such genotypes (GG, AG+GG) appeared same OR for patient with cervical cancer in study group (OR = 0.12, 95% CI = 0.04-0.39-P < 0.001-OR = 0.5 ,95% CI = 0.25-0.95-P = 0.03). There was decrease risk of cervical cancer in user of oral contraceptive with AG and GG genotypes of TAP2 (OR = 0.55, 95% Cl = 0.41-0.73, P = 0.002, OR = 0.09, 95% CI = 0.02-0.36, P < 0.001) respectively. In case of TAP1 gene all allelic polymorphisms showed a decrease OR in patients with cervical cancer in passive smokers and user of oral contraceptives, though, no significant
Thus, TAP1 and TAP2 genes polymorphism are not linked to cervical carcinoma, since no association was found between a particular genotype and the disease.
抗原加工相关转运体(TAP)是ATP结合盒转运体超家族的成员,由两种整合膜蛋白TAP-1和TAP-2组成。TAP基因产物参与与MHC I类分子结合的内源性肽的加工。这些基因内的突变和/或多态性可能会改变免疫反应的效力,这可能与自身免疫性疾病和癌症的发生有关。
从200例宫颈癌患者和200例健康对照者的外周血样本中分离DNA。通过聚合酶链反应确定TAP1和TAP2等位基因多态性。
在鳞状细胞癌患者中,分别观察到TAP2的GG和AG+GG组合基因型具有显著的保护优势比(OR = 0.22,95%CI = 0.09-0.51,P < 0.001;OR = 0.47,95%CI = 0.24-0.92,P = 0.02)。同样,在研究组的宫颈癌患者中,此类基因型(GG,AG+GG)显示出相同的优势比(OR = 0.12,95%CI = 0.04-0.39,P < 0.001;OR = 0.5,95%CI = 0.25-0.95,P = 0.03)。携带TAP2的AG和GG基因型的口服避孕药使用者患宫颈癌的风险降低(OR分别为0.55,95%Cl = 0.41-0.73,P = 0.002;OR = 0.09,95%CI = 0.02-0.36,P < 0.001)。对于TAP1基因,在被动吸烟者和口服避孕药使用者的宫颈癌患者中,所有等位基因多态性均显示优势比降低,不过差异无统计学意义。
因此,TAP1和TAP2基因多态性与宫颈癌无关,因为未发现特定基因型与该疾病之间存在关联。